Patient factors influencing the selection Of glucose-lowering drugs Other than SGLT2i and metformin in T2D and CKD.
ASCVD. atherosclerotic cardiovascular disease:
CKD. chronic kidney disease,
DPP4i, dipeptidyl peptidase—4 inhibitor,
eGFR. estimated glomerular filtration rate
GLP IRA. glucagon-like peptide- I receptor agonist
SGLT2i. sodium-glucose cotransporter-2 inhibitor;
SU, sulfonylurea; T2D. type 2 diabetes; TZD, thiazolidinedione.
type 2 diabetes; TZD,
#KDIGO2020 #CKD #Diabetes Management in CKD #management #treatment #CHART